As the burden of cancer continues to rise globally, there is an urgent need for effective therapies for hard-to-target cancers associated with particularly poor outcomes.
HOX’s targeted approach (HTL-001) and dual androgen receptor programme (HTL-003) have potential applicability across many cancer types, offering novel modalities to develop therapeutics.
HOX is focused on developing innovative therapeutics for prostate cancer for which there is a huge unmet medical.
Hox Therapeutics 